Objectives: In April 1998, the Medical Services Advisory Committee (MSAC) was established by the Australian federal government. Since that time, all new medical procedures must be evaluated for safety, effectiveness, and cost-effectiveness as a condition of the surgeon receiving public funding by means of the Medicare Benefits Schedule (MBS). Over these first 8 years, a significant number of applications for the public funding of new procedures have been given negative recommendations by the MSAC based on insufficient clinical evidence or lack of cost-effectiveness. In August 2006, after almost 2 years of processing, the MSAC made the decision to fund the new procedure, laparoscopic remotely assisted radical prostatectomy (LRARP). However, they stated that there was still uncertainty about the comparative cost-effectiveness.

Methods: An observational study using provisional cost-utility data for LRARP based on a combination of costs taken from consecutive patients at the Epworth Hospital, Melbourne, Australia, and utilities from the prospectively collected data on all patients undergoing surgery for prostate cancer over a 4-year period at the Vattikuti Urology Institute, Michigan, United States.

Results: The incremental cost for LRARP compared with the open surgery alternative is A$2,264 or A$24,457 per quality-adjusted life-year, well below the range accepted by the Australian pharmaceutical equivalent of the MSAC (the PBAC) of A$42,000 and A$76,000. This figure does not take into account additional benefits such as reduced time away from employment, reduced blood loss, reduced possibility of infection, and reduced scarring.

Conclusions: This case study of LRARP demonstrates that there is sufficient crude evidence to show that this new procedure is likely to be superior to the existing procedure in terms of safety, effectiveness, and cost-effectiveness. The decision to allow MBS funding was correct and will allow for the collection of additional evidence, on both economic and clinical outcomes.

The anti-emetic efficacy of prophylactic ondansetron and tropisetron in combination with a low dose of droperidol in patients with high probability for post-operative nausea and vomiting undergoing gynaecological laparoscopy was compared. Patients were randomly allocated in a double-blind manner to receive either ondansetron 8 mg (n=45) or tropisetron 5 mg (n=43) at the end of surgery. A standardized general anaesthetic technique was used, including droperidol 0.75 mg. The incidence of nausea was 36% and 49% (P=0.28), and vomiting occurred in 13% and 14% of the patients in the ondansetron and tropisetron groups, respectively. The onset time for rescue medication was significantly sooner after tropisetron than ondansetron (3 h 18min vs. 6 h 25min; P=0.007). There were no statistically significant differences in efficacy between prophylactic ondansetron and tropisetron combined with droperidol in a high-risk population. However, ondansetron appeared to be more effective in preventing post-operative nausea and vomiting in the early hours after surgery compared with tropisetron.

We studied the haemodynamic changes induced by pneumoperitoneum (PP) in elderly patients with increased cardiac risk (ASA class III; n = 10; age 72.3 ± 8.8 years, mean±SD, P < 0.05; group 2) and compared the results with patients at normal risk (ASA class I, II; n = 12; age 55.6 ± 11.8 years; group 1). Thermodilution measurements were performed after induction of general anaesthesia (T1), after onset of PP (T2, intraabdominal pressure 14 mmHg) and after additional 15° head-up tilt (T3). In both groups PP, as compared with T1, induced a significant increase in mean arterial pressure (MAP, mmHg, group 1:77 ± 14 to 96 ± 18, P < 0.05/group 2:75 ± 10 to 102 ± 18, P < 0.01), mean pulmonary artery pressure (MPAP, mmHg: 15 ± 5 to 22 ± 4, P < 0.01/18 ± 3 to 25 ± 5, P < 0.01), central venous pressure (CVP, mmHg: 7 ± 2 to 15 ± 3, P < 0.01/7 ± 2 to 12 ± 2, P < 0.01), pulmonary capillary wedge pressure (PCWP, mmHg: 9 ± 4 to 16.3, P < 0.01/8 ± 2 to 15 ± 6, P < 0.01) and in systemic vascular resistance (SVR, dynes s cm−5: 1415 ± 375 to 1873 ± 412, P < 0.01/1502 ± 360 to 2067 ± 647, P < 0.01). Cardiac index (CI, L min−1 m−2: 2.3 ± 0.3 to 1.9 ± 0.3, P < 0.05/2.2 ± 0.4 to 2.2 ± 0.5 P = 0.76) and oxygen delivery index (DO2I, mL min−1 m−2: 388 ± 54 to 324 ± 61, P < 0.05/358 ± 69 to 353 ± 82, P = 0.77) decreased in group 1 but not in group 2. Heart rate, stroke index, pulmonary vascular resistance, arteriovenous oxygen content difference and oxygen consumption index were unchanged. After head-up tilt MAP (mmHg, 92 ± 15, P < 0.05/101 ± 17, P < 0.01), MPAP (mmHg, 20 ± 3, P < 0.01/22 ± 4, P < 0.05), CVP (mmHg, 12 ± 2, P < 0.01/10 ± 2, P& lt; 0.01) and PCWP (mmHg, 12 ± 3, P < 0.05/12 ± 5, P < 0.05) remained elevated compared with T1 in both groups, SVR (dynes s cm−5, 1575 ± 372, P = 0.13/1793 ± 528, P < 0.01) in group 2 only. No complications occurred. The results indicate that PP is associated with significant but relatively benign haemodynamic changes. Anaesthesia for laparoscopic cholecystectomy may be performed safely also in elderly ASA class III patients with increased cardiac risk. An adequate haemoto dynamic monitoring is recommended.